[{"address1": "5 Science Park", "address2": "395 Winchester Avenue", "city": "New Haven", "state": "CT", "zip": "06511", "country": "United States", "phone": "203 535 1456", "website": "https://www.arvinas.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.", "fullTimeEmployees": 445, "companyOfficers": [{"maxAge": 1, "name": "Dr. John G. Houston Ph.D.", "age": 63, "title": "Chairperson, CEO & President", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1144497, "exercisedValue": 0, "unexercisedValue": 12278804}, {"maxAge": 1, "name": "Dr. Ian  Taylor Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 732256, "exercisedValue": 0, "unexercisedValue": 1344633}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 24.46, "open": 24.42, "dayLow": 24.355, "dayHigh": 26.57, "regularMarketPreviousClose": 24.46, "regularMarketOpen": 24.42, "regularMarketDayLow": 24.355, "regularMarketDayHigh": 26.57, "beta": 1.982, "forwardPE": -5.648472, "volume": 1049426, "regularMarketVolume": 1049426, "averageVolume": 746153, "averageVolume10days": 905900, "averageDailyVolume10Day": 905900, "bid": 25.78, "ask": 25.91, "bidSize": 500, "askSize": 300, "marketCap": 1770333440, "fiftyTwoWeekLow": 13.57, "fiftyTwoWeekHigh": 53.08, "priceToSalesTrailing12Months": 24.829361, "fiftyDayAverage": 30.8152, "twoHundredDayAverage": 32.22055, "currency": "USD", "enterpriseValue": 603633024, "floatShares": 56901802, "sharesOutstanding": 68431904, "sharesShort": 8252407, "sharesShortPriorMonth": 8661254, "sharesShortPreviousMonthDate": 1714435200, "dateShortInterest": 1717113600, "sharesPercentSharesOut": 0.12060001, "heldPercentInsiders": 0.071550004, "heldPercentInstitutions": 1.02587, "shortRatio": 11.56, "shortPercentOfFloat": 0.1228, "impliedSharesOutstanding": 68431904, "bookValue": 8.927, "priceToBook": 2.8979502, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -354800000, "trailingEps": -6.05, "forwardEps": -4.58, "pegRatio": 0.21, "enterpriseToRevenue": 8.466, "enterpriseToEbitda": -1.539, "52WeekChange": -0.009571195, "SandP52WeekChange": 0.24598539, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ARVN", "underlyingSymbol": "ARVN", "shortName": "Arvinas, Inc.", "longName": "Arvinas, Inc.", "firstTradeDateEpochUtc": 1538055000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "5ab3d208-4f36-3880-916e-a34548e61b36", "messageBoardId": "finmb_243040896", "gmtOffSetMilliseconds": -14400000, "currentPrice": 25.87, "targetHighPrice": 110.0, "targetLowPrice": 38.0, "targetMeanPrice": 68.44, "targetMedianPrice": 66.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 18, "totalCash": 1169299968, "totalCashPerShare": 17.087, "ebitda": -392300000, "totalDebt": 2600000, "quickRatio": 4.885, "currentRatio": 4.943, "totalRevenue": 71300000, "debtToEquity": 0.426, "revenuePerShare": 1.186, "returnOnAssets": -0.20783001, "returnOnEquity": -0.63318, "freeCashflow": -210987504, "operatingCashflow": -354100000, "revenueGrowth": -0.222, "grossMargins": 1.0, "operatingMargins": -3.29249, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-27"}]